 Anavex Life Sciences Corp NASDAQ: AVXL has reported that SIGMAR1 mRNA expression correlates positively with responses in efficacy endpoints in the Phase 2 trial of ANAVEX 2-73 blarcamesine in patients with Parkinsons disease dementia. ANAVEX 2-73 activates the sigma-1 receptor SIGMAR1, restoring neural cell homeostasis and promoting neuroplasticity. 